Research Vault — Institutional Desk Research

The desk research, the way the analysts wrote it. 分析师原文研报，原汁原味呈现。

Showing the latest saved institutional reports.Refreshing the latest institutional reports. New buy-side and sell-side desk reports land here hourly — read the ones that touch what you hold. 正在显示最近保存的机构研报。正在刷新最新机构研报。买方与卖方研究每小时更新至此 —— 挑与你持仓相关的读。

The research the desks write for their clients — now on yours. 机构写给客户的研报 —— 现在也在你手中。

—

New this week本周新增

—

Desks publishing在发机构

—

Most-covered theme覆盖最多主题

—

In the vault库内总量

OTOtherIND

mom

**S&P 500 FCF Margin Divergence**: FCF margins (green) show sectoral divergence vs.
resilient operating margins (blue), signaling cash flow sustainability as critical financial health metric amid inflation and AI-driven capital spending.
**Sector Rotation & Credit Stress**: S&P 500 IT down -7.76% (vs.
Banks +33.81% earnings growth) signals leadership shift to Energy/Financials; hyperscalers’ CDS spreads at record levels highlight credit risk in tech, pressuring valuations amid rising rates.

Aug 3, 2026 · 23:02 UTC

UBUBSSELLHighlighted

Daily US

**Earnings/Disinflation Catalyst**: Megacap tech earnings (cloud revenue acceleration, hyperscaler spending) and moderating inflation support Fed rate hold; US-Iran tensions drive oil volatility but energy flows recovery expected.
**Global Earnings Momentum**: S&P 500 Q2 earnings growth estimate at 20% YoY, Europe Stoxx 600 upgrades, Asia profits rising 72%—fundamentals drive broad equity rally.
**Yen Vulnerability**: Japan’s coordinated yen-buying (USDJPY 156.7) caps near-term upside but underlying drivers (BoJ normalization, negative real rates) persist; geopolitics and policy flows keep yen weak.

Aug 3, 2026 · 22:44 UTC

GSGoldman SachsSELL

Shionogi (4507)

**High leverage risk**: Net debt/equity 20.0x (3/26) and leverage 1.5x (3/26) indicate significant financing vulnerability despite positive cash flows.
**Patent cliff & growth catalysts**: Core HIV treatment dolutegravir patent expiry approaching; sustainable earnings depend on long-acting HIV formulations, edaravone sales, and Japan Tobacco synergies.
**Critical risks**: Downside in key drug sales, development delays, Xofluza/Xocova sales volatility (flu/COVID-19 linked), forex, pricing/tariffs, and reimbursement changes.
**Price target confidence**: Goldman Sachs target ¥3,500 consistently exceeds current price (e.g., ¥2,843 on 16-Jul-26), signaling strong analyst conviction and upside potential.

Aug 3, 2026 · 22:26 UTC

695 more institutional reports还有 695 篇机构研报

You’re previewing the latest three summaries. Upgrade to Pro to open every desk and read the full PDFs.你正在预览最新三篇摘要。升级 Pro 即可查看全部机构研报并阅读 PDF 全文。

Upgrade to Pro升级 Pro

The desk research, the way the analysts wrote it. 分析师原文研报，原汁原味呈现。

Highlighted this week本周精选

mom

Daily US

Shionogi (4507)

Pro research report

695 more institutional reports还有 695 篇机构研报